Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
60.95
-0.75 (-1.22%)
Mar 23, 2026, 4:00 PM EDT - Market closed
Cytokinetics Employees
Cytokinetics had 673 employees as of December 31, 2025. The number of employees increased by 175 or 35.14% compared to the previous year.
Employees
673
Change (1Y)
175
Growth (1Y)
35.14%
Revenue / Employee
$130,816
Profits / Employee
-$1,166,352
Market Cap
7.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 673 | 175 | 35.14% |
| Dec 31, 2024 | 498 | 75 | 17.73% |
| Dec 31, 2023 | 423 | 14 | 3.42% |
| Dec 31, 2022 | 409 | 156 | 61.66% |
| Dec 31, 2021 | 253 | 69 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 238 |
| Nuvalent | 228 |
CYTK News
- 5 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 7 days ago - Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo - GlobeNewsWire
- 12 days ago - Cytokinetics, Incorporated (CYTK) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Cytokinetics to Participate in March Investor Conferences - GlobeNewsWire
- 27 days ago - Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 27 days ago - Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 5 weeks ago - Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - GlobeNewsWire